It was previously shown that sphingomyelin and gangliosides can be biosynthesized starting from sphingosine or sphingosine-containing fragments which originated in the course of GM1 ganglioside catabolism. In the present paper we investigated which fragments were specifically re-used for sphingomyelin and ganglioside biosynthesis in rat liver. At 30 h after intravenous injection of G labelled at the level of the fatty acid or of the sphingosine moiety, it was observed that radioactive sphingomyelin was formed almost exclusively after the sphingosine-labelled-Gm1 administration. This permitted the recognition of sphingosine as the metabolite re-used for sphingomyelin biosynthesis. Conversely, gangliosides more complex than GM1 were similarly radiolabelled after the two treatments, thus ruling out sphingosine re-utilization for ganglioside biosynthesis. For the identification of the lipid fragment re-used for ganglioside biosynthesis, we administered to rats neutral glycosphingolipids (galactosylceramide, glucosylceramide and lactosylceramide) each radiolabelled in the sphingosine moiety or in the terminal sugar residue. Thereafter we compared the formation of radiolabelled gangliosides in the liver with respect to the species administered and the label location. After galactosylceramide was injected, no radiolabelled gangliosides were formed. After the administration of differently labelled glucosylceramide, radiolabelled gangliosides were formed, regardless of the position of the label. After lactosylceramide administration, the ganglioside fraction became more radioactive when the long-chain-base-labelled precursors were used. These results suggest that glucosylceramide, derived from glycosphingolipid and ganglioside catabolism, is recycled for ganglioside biosynthesis.
INTRODUCTION
Ganglioside metabolism and intracellular transport has been recently studied by the use of an approach consisting of the administration of radiolabelled gangliosides to animals or to cultured cells, followed by recognition of the steps of their metabolic processing. Application of this approach enabled us to demonstrate that exogenous gangliosides penetrate into cells and undergo the following metabolic processes: (i) direct glycosylation to more complex analogues (Ghidoni et al., 1983; Sonderfeld et al., 1985; Trinchera et al., 1990) ; (ii) lysosomal degradation with release of fragments that are re-utilized for biosynthetic purposes. The latter process was investigated in detail, and it was ascertained that different glycoconjugates can be biosynthesized from sialic acid, N-acetylgalactosamine and galactose of ganglioside origin (Ghidoni et al., 1987 (Ghidoni et al., , 1989 Trinchera et al., 1990) . Moreover, it was found that sphingomyelin and gangliosides themselves can be biosynthesized starting from sphingosine or some sphingosine-containing fragment, originated in the course of ganglioside catabolism (Ghidoni et al., 1986) . We recently reported (Trinchera et al., 1988) that sphingosine is specifically recycled for sphingomyelin biosynthesis in human fibroblasts feeded with sulphatide. The present paper is aiming to elucidate which fragments originating in the course of ganglioside catabolism are re-used for sphingomyelin and ganglioside biosynthesis and whether this is a specific process. This question appears to be of additional interest after the recent claims (Hannun & Bell, 1989; Igarashi et al., 1989) that sphingosine or sphingosine derivatives may serve as intracellular second messengers.
The experimental approach we adopted was to inject rats with GMl radiolabelled on the sphingosine ([Sph-3H]GMl) or on the fatty acid ([stearoyl-14C]GMl) moiety and to examine the radioactive metabolites, from both the catabolic and biosynthetic pathways, formed in the liver after an established time. This approach permitted us to recognize sphingosine as the metabolite re-used for sphingomyelin biosynthesis. Furthermore, to address the characterization of the sphingosine-carrying fragment reused for ganglioside biosynthesis, we injected neutral glycosphingolipids [galactosylceramide (GalCer), glucosylceramide (GlcCer) and lacytosylceramide (LacCer)], previously radiolabelled in definite positions of the molecule, and monitored the incorporation of radioactivity into gangliosides. All the administered compounds were homogeneous in their lipid moiety and contained erythro-C.8-sphingosine as the long-chain base (LCB) and stearic acid as the fatty acid. Using this approach we were able to ascertain that GlcCer is recycled for ganglioside biosynthesis.
EXPERIMENTAL Preparation of gangliosides and neutral glycosphingolipids
Gangliosides GM3, GM2, GM1, GD1, and GTlb, used for animal treatment (GM.) or as reference standards (all the others) were prepared in pure form (over 99 %) from bovine brain as described by Tettamanti et al. (1973) .
GlcCer and LacCer were prepared by partial acid hydrolysis of a bovine brain ganglioside mixture. Briefly, 100 mg of bovine brain ganglioside mixture was hydrolysed in 20 ml of 0.5 M-HCI for 4 h at 80 'C. At the end of the reaction, after neutralization Vol. 270 Abbreviations used: DDQ: 2,3-dichloro-5,6-dicyanobenzoquinone; LCB, long-chain base; Sph (in radiolabelled compounds), C18 sphingosine [(2S,3R,4E)-2-amino-4-octadecene-1,3-diolj; for glycolipid and ganglioside designation, the nomenclature of Svennerholm (1964) with NaOH, the solution was dialysed overnight against distilled water (changed twice) and finally freeze-dried. Purification of GlcCer and LacCer was done by silica-gel column chromatography, using chloroform/methanol/water (55:20:3, by vol.) as the eluting solvent. The final yield was 4 mg of GIcCer and 15 mg of LacCer. GalCer was prepared by re-acylation of commercial psycocine (galactosyl-C18-sphingosine) (Sigma) with stearic acid by the method of Dubois et al. (1980) .
Radiolabelling methods
GM1 ganglioside was isotopically radiolabelled in one of the following positions of the molecule: C-3 of the LCB ([Sph-3H]GM1) and C-1 of the stearic acid ([stearoyl-14C]GMl). 3H-labelling at the level of C-3 of the LCB was performed by the 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ)/NaB3H4 procedure (Ghidoni et al., 1981) ; 14C-labelling of GMl on the stearic acid residue was carried out by the deacylation/reacylation method (Acquotti et al., 1986) , using [14C]stearic acid.
GalCer, GlcCer and LacCer were labelled in one of the following positions of the molecule: C-3 of the sphingosine base and C-6 of the terminal sugar residue. Labelling at the level of sphingosine C-3 was performed, in all cases, by the DDQ/NaB3H4 procedure (Iwamori etal., 1975) . Labelling at the level of the terminal sugar residue was accomplished by the galactose oxidase/NaB3H4 procedure (Leskawa et al., 1984) , for GalCer and LacCer, and by the procedure of McMaster & Radin (1976) , which involves oxidation of the C-6 hydroxy group, by the Pfitzner-Moffat reaction, followed by NaB3H4 reduction, in the case of GIcCer. Reference ceramide was prepared by acid treatment of GalCer (Ghidoni et al., 1986 ).
In the course of the preparation of radiolabelled compounds, steps aiming to obtain a high homogeneity in the LCB moiety were required at different stages of the procedure. Purifications were done by reversed-phase h.p.l.c. (Sonnino et al., 1984; Hirabayashi etal., 1986) or by silica-gel column chromatography using the following eluting solvent systems: (I) chloroform/ methanol (19:1, v/v) and (II) chloroform/methanol/water (625:100:2, by vol.).
The radiochemical purity of all radiolabelled compounds, assessed immediately before animal treatment, was over 99 %. The LCB composition and assessment of the C-3 steric configuration in both underivatized and radiolabelled compounds was performed by g.l.c.-m.s. or radio-g.l.c., as previously described (Sonnino et al., 1984) .
Animals and animal treatment
Adult male Wistar rats (Charles River, Milan, Italy), 60 days old and 100 g average body weight, were employed. The animals were kept, until the day before injection and during treatment, under the following conditions: light, from 06:00 to 18:00 h; temperature, 20 'C; food and water ad libitum. During the 24 h before injection, no food was given. Each animal was intravenously (i.v.) injected in the tail, between 08:00 and 10:00 h, without anaesthesia with (i) labelled GMl dissolved in 0.1 ml of sterile physiological solution (Ghidoni et al., 1986) ; the total radioactivity injected was 50,Ci for [Sph-3H]GMl and 2.5 ,Ci for [stearoyl-'4C]GMl (both accounting for about 50 nmol of GM1); ii) 0.1 ml of a dispersion freshly prepared as described by Pentchev et al. (1981) , containing 50 ,Ci of radioactive GlcCer; (iii) 0.1 ml of a dispersion freshly prepared by the method of Soriano et al. (1983) , containing 50,uCi of radioactive GalCer or LacCer. In these forms of administration both gangliosides and neutral glycosphingolipids have previously been reported to be actively incorporated and metabolized in the liver, with a main role being played by the parenchymal cells (Pentchev et (Tettamanti etal., 1973) , three fractions being obtained. The organic phase obtained, containing lipids of a non-ganglioside nature, was evaporated to dryness before processing and referred to as the 'non-ganglioside lipid fraction'. The obtained aqueous phase was further purified by DEAE-Sepharose chromatography (Ghidoni et al., 1986) Ghidoni et al. (1986) , using sphingomyelinase treatment (Ikezawa et al., 1978) . Neutral sphingolipids formed were recognized by t.l.c. comparison with authentic reference compounds.
Gangliosides were separated by t.l.c. using chloroform/ methanol/aq. 0.2% CaCl2 (60:42:11, by vol.) as the eluting solvent system. Individual gangliosides present in the liver were identified as described by Ghidoni et al. (1986) , and also by using Vibrio cholerae sialidase (Ghidoni et al., 1987) for 18 h. These conditions were selected since they produced, concurrently, and in a good yield, LacCer, GlcCer and ceramide.
The same conditions were too drastic to enable formation of asialo-GMl and asialo-GM2, which were insignificant for our purpose. T.l.c. separation of the products obtained was done using chloroform/methanol/water (55:20:3, by vol.) as the eluting solvent system. Degradation products resulting after acid treatment were identified by co-chromatography with reference compounds.
Determination of radioactivity Determination of radioactivity by fluorography, radiochromatography or liquid-scintillation counting in solution was performed as previously described (Ghidoni et al., 1986) .
RESULTS
Distribution of incorporated radioactivity after administration of radiolabelied GM1 ganglioside phase (non-ganglioside lipids) is much higher than with the sphingosine-3H label, whereas the radioactivity contained in the dialysed aqueous phase (ganglioside fraction) is almost identical in both cases. Practically no radioactivity was present in the delipidized pellet (protein material). As Table 2 shows, the distribution of radioactivity in the different liver gangliosides was practically identical, regardless of the position of the label in the injected GM1, and the major portion of radioactivity was associated with GM1. Conversely, the radioactivity distribution in the different lipids ofnon-ganglioside nature varied considerably as a function of the ganglioside administered. After [Sph-3H]GMl injection, sphingomyelin and ceramide were the main radioactive compounds formed (Fig. 1 1, lane 3) . Confirmation of the nature of these compounds was obtained by submitting the dried organic phase to alkaline methanolysis. In the case of [stearoyl-'4C]GMl administration, the main radioactive spots, affected by alkali, disappeared with the formation of a dominant compound, moving to the fatty acid region (Fig. 1, lane 4) .In the case of [Sph-3H]GMl administration, no modification in the pattern of radioactive compounds was caused by alkali treatment (Fig. 1, lane 2) .
Distribution of incorporated radioactivity after administration of neutral glycosphingolipids Table 3 shows the radioactivity incorporated into the dried organic phase and dialysed aqueous phase 30 h after i.v. injection of GalCer, LacCer and GlcCer, bearing the radioactivity in different sites of the molecule. In all cases, the incorporated radioactivity was mainly recovered in the dried organic phase, and the delipidized pellet was virtually rid of bound radioactivity. A much greater amount of incorporated radioactivity was recorded in the dried organic phase with the label on the sphingosine than in the terminal sugar moiety.
With regard to the radioactivity incorporated into gangliosides, it was present after administration of GlcCer and LacCer, and absent after GalCer. The incorporation of radioactivity into gangliosides in the case of GIcCer administration had very similar values, with both [Glc-3H]GlcCer and [Sph-3H]GlcCer, whereas after LacCer treatment the value was 3.5-fold higher with [Sph-3H]LacCer than with LacCer. The distribution of incorporated radioactivity into the individual compounds present in the dried organic phase after administration of GlcCer, GalCer and LacCer carrying the label at the level of the sphingosine moiety is reported in Table 4 . In particular, ceramide and sphingomyelin were produced after each treatment. It is also noteworthy that, after administration of [Sph-3HjLacCer, radiolabelled glucosylceramide was produced too.
The pattern of radioactive gangliosides obtained after administration oflabelled glucosylceramide and lactosylceramide are reported in Fig. 2 . In all cases, the distribution of radioactivity among the different gangliosides was similar, with GM3-being the main radioactive compound (45-50 % of total gangliosideassociated radioactivity), followed by GDla and GM, (20-25 %) and GD1b (3-4 %). The absolute values of radioactivity present in the different gangliosides were almost identical after the injection of equal amounts of [Glc-3H]GlcCer and [Sph-3H]GlcCer, whereas in the case of LacCer administration the values were much greater (3-4-fold) with [Sph-3H]LacCer than with [Gal-3H]LacCer.
The intramolecular distribution of the radioactivity introduced into liver gangliosides after administration of labelled GIcCer and LacCer was determined by using purified GM. (Fig.   3 ). In the case of GMD obtained from [Glc-3H]GlcCer, the radioactivity was recorded in the peaks corresponding to LacCer and GlcCer, in a ratio similar to that obtained when reference GMl underwent the same acid treatment. In this case, radioactive ceramide was also formed. In the case of gangliosides derived from [Gal-3H]LacCer treatment, only the peak corresponding to LacCer was found to be radioactive. The acid treatment was done as described in the Experimental section. The radioactive lipids obtained by acid treatment of GM1 were separated by t.l.c., using chloroform/methanol/water (55:20:3, by vol.) as the eluting solvent, and the plates were submitted to radiochromatographic scanning.
DISCUSSION
Previous papers (Ghidoni et al., 1986 (Ghidoni et al., , 1989 Sonderfeld et al., 1985) (Gatt, 1970) , the question as to whether such molecules cross the lysosomal membrane by a carrier-mediated process or leave the organelle by a vesiculation mechanism still remains and deserves further investigation.
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